Recent events
Recent events tied to this brand in public sources.
Back to profile56 entries · Page 2 of 3
2023
XtalPi and Eli Lilly sign AI drug-discovery partnership
XtalPi announced that it signed an AI small-molecule drug-discovery collaboration with Eli Lilly. XtalPi will develop and deliver candidate compounds for an undisclosed target, and Lilly will handle subsequent development and commercialization.
2023
Lilly announces insulin price reductions and a $35 monthly out-of-pocket cap
Eli Lilly announced a 70% reduction in list prices for its most commonly prescribed insulins and expanded its Insulin Value Program to cap out-of-pocket costs at $35 or less per month. Some price changes were scheduled to take effect later in 2023; the company said the actions were intended to improve insulin affordability and access.
2023
Lilly announces Rezvoglar launch at a discounted price
Eli Lilly announced that it would launch Rezvoglar, a basal insulin biosimilar to and interchangeable with Lantus, for $92 per five-pack of KwikPens, effective April 1, 2023.
2023
PrescriberPoint announces Series Seed investment
PrescriberPoint announced a Series Seed investment in which Eli Lilly and Company, Pfizer Inc., Adobe Inc., and Mastercard Incorporated participated.
2023
Eli Lilly and former employee agree to settle whistleblower lawsuit
Eli Lilly and former employee Amrit Mula agreed to settle a lawsuit in which Mula alleged that she was terminated after raising concerns about manufacturing practices and data falsification involving company drugs. Lilly said the resolution in no way admitted wrongdoing; settlement details were not disclosed in the article.
2022
Ramiven receives approval for an additional early breast cancer indication
Eli Lilly and Company (India) said its breast cancer drug Ramiven received regulatory approval for an additional indication: treating certain high-risk early breast cancer patients in combination with endocrine therapy.
2022
FDA approves expanded Retevmo indications
The FDA approved Retevmo for certain adult patients with locally advanced or metastatic solid tumors with a RET gene fusion, and granted traditional approval for its use in adult patients with locally advanced RET fusion-positive NSCLC. Eli Lilly said the action broadened the drug's label and converted its May 2020 accelerated NSCLC approval to traditional approval.
2022
FDA approves expanded Retevmo indication
Eli Lilly announced that the U.S. Food and Drug Administration approved Retevmo for certain adult patients with advanced or metastatic solid tumors with a RET gene fusion. The FDA also granted traditional approval for Retevmo for adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer.
2022
FDA approves Mounjaro for adults with type 2 diabetes
The U.S. Food and Drug Administration approved Eli Lilly's Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
2022
Artax Biopharma closes $26 million financing
Artax Biopharma announced that it closed a $26 million financing round to develop AX-158. Eli Lilly and Company and Sound Bioventures participated as new investors alongside existing investors.
2022
NeoGenomics and Lilly partner on lung cancer testing program
NeoGenomics announced a partnership with Eli Lilly and Company on a sponsored testing program offering eligible patients with metastatic non-small cell lung cancer testing at no cost.
2022
FDA approves Jardiance for adults with heart failure
The FDA approved Boehringer Ingelheim's drug Jardiance, co-developed with Eli Lilly, to mitigate the risk of cardiovascular death and hospitalization for heart failure in adults.
2022
Arkuda Therapeutics completes $64 million Series B financing
Arkuda Therapeutics announced completion of a $64 million Series B financing co-led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from other new and existing investors. The company said the funding would support advancement of its lead program and expansion of its pipeline.
2021
Mozart Therapeutics announces $55 million Series A financing
Mozart Therapeutics announced a $55 million Series A financing led by ARCH Venture Partners, with Sofinnova Partners and additional investors participating. The company said it would use the funds to advance its lead CD8 Treg Modulator into the clinic and progress additional programs.
2021
FDA approves expanded Verzenio adjuvant-treatment use
The FDA approved Eli Lilly's Verzenio, in combination with endocrine therapy, for adjuvant treatment of certain adults with high-risk, node-positive, HR-positive/HER2-negative early breast cancer.
2021
Healthcare Pharmaceuticals launches Cyramza in Bangladesh
Healthcare Pharmaceuticals launched Cyramza, an injectable anti-cancer medicine, in Bangladesh in association with Eli Lilly and Company.
2021
Lilly and Lycia sign collaboration and licensing agreement
Eli Lilly and Lycia Therapeutics signed a multi-year collaboration and licensing agreement to discover, develop and commercialize therapeutics targeting areas including immunology and pain. Lilly will lead preclinical and clinical development and receive an exclusive worldwide commercialization license for potential medicines developed under the agreement.
2021
Menarini completes acquisition of Cialis in China
A. Menarini Asia-Pacific Holdings, part of Menarini Group, announced that it had completed its acquisition of Eli Lilly's Cialis brand in China and would take over the brand's ownership, sales, marketing and distribution.
2021
Arecor announces formulation study collaboration with Lilly
Arecor announced that it had signed a formulation study partnership with Eli Lilly and Company. Arecor said the collaboration concerns the potential development of a new formulation for a Lilly product.
2021
Natco and Lilly sign Baricitinib licensing agreement
Natco Pharma announced that it signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company to manufacture and commercialize Baricitinib for COVID-19 in India.